ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2310건의 자료가 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2142 | Recruiting | A Study To Assess The Efficacy and Safety of HH-120 Nasal Spray for the Treatment of Mild COVID-19 | COVID-19 | Drug: HH-120 nasal spray Drug: HH-120 nasal spray Drug: Placebo Comparator Drug: Placebo Comparator |
Phase 2 | Huahui Health | INDUSTRY | 200 | All | 18 Years | Beijing Ditan Hospital, Capital Medical University, Beijing, Beijing, China Beijing Friendship Hospital,Capital Medical University, Beijing, Beijing, China Peking University Third Hospital, Beijing, Beijing, China Mengchao Hepatobiliary Hospital Of Fujian Medical University, Fuzhou, Fujian, China The People's Hospital of Gaozhou, Gaozhou, Guangdong, China Nanfang Hospital,Southern Medical University, Guangzhou, Guangdong, China Xiangtan Central Hospital, Xiangtan, Hunan, China Lianyungang Oriental Hospital, Lianyungang, Jiangsu, China Yixing People's Hospital, Wuxi, Jiangsu, China The First Hospital of Jilin University, Changchun, Jilin, China Panjin Liaoyou Gem flower Hospital, Panjin, Liaoning, China Linfen Central Hospital, Linfen, Shanxi, China Chengdu Second People's Hospital, Chengdu, Sichuan, China Qujing First People's Hospital, Qujing, Yunan, China Southern Central Hospital Of Yunnan Province(The First People's Hospital Of Honghe State), Honghe, Yunnan, China Wenzhou Traditional Chinese Medicine Hospital, Wenzhou, Zhejiang, China |
| 2141 | Completed | A Study to Assess the Efficacy and Safety of XC221 in Patients With COVID-19 | SARS-CoV-2 Infection | Drug: XC221 Drug: Placebo |
Phase 3 | RSV Therapeutics LLC | INDUSTRY | 118 | All | 18 Years ~ 75 Years | Municipal Budgetary Institution of Healthcare "Central City Hospital of Novoshakhtinsk", Novoshakhtinsk, Rostov Region, Russian Federation Saint Petersburg State Budgetary Institution of Healthcare "City Hospital No. 40 of Kurortny District", Saint Petersburg, Russian Federation Saint Petersburg State Budgetary Institution of Healthcare "City Pokrovskaya Hospital" (4th Cardiology Department), Saint Petersburg, Russian Federation Saint Petersburg State Budgetary Institution of Healthcare "City Pokrovskaya Hospital", Saint Petersburg, Russian Federation Regional State Budgetary Institution of Healthcare "Medical-Sanitary Unit No. 2", Tomsk, Russian Federation |
| 2140 | Completed | A Study to Assess the Efficacy and Safety of XC221 in Patients With Mild COVID-19 | Sars-CoV-2 Infection | Drug: XC221 Drug: Placebo |
Phase 3 | RSV Therapeutics LLC | INDUSTRY | 274 | All | 18 Years ~ 75 Years | Municipal Budgetary Institution of Healthcare "Central City Hospital of Novoshakhtinsk", Novoshakhtinsk, Rostov Region, Russian Federation LLC "Family Clinic", Ekaterinburg, Russian Federation Regional Budgetary Institution of Healthcare "Ivanovskaya Clinical Hospital named after Kuvaevykh", Ivanovo, Russian Federation State Budgetary Institution of Healthcare of Moscow "City Polyclinic No. 2 of the Moscow Department of Healthcare", Moscow, Russian Federation Federal Budgetary Institution of Science "Moscow Research Institute of Epidemiology and Microbiology named after G.N. Gabrichevsky" of the Federal Service for the Oversight of Consumer Protection and Welfare, Moscow, Russian Federation Limited Liability Company "Medical Center "Capital-Policy", Saint Petersburg, Russian Federation Limited Liability Company "Research Center Eco-Safety", Saint Petersburg, Russian Federation LLC "Sphere-Med", Saint Petersburg, Russian Federation Saint Petersburg State Budgetary Institution of Healthcare "City Pokrovskaya Hospital" (4th Cardiology Department), Saint Petersburg, Russian Federation Saint Petersburg State Budgetary Institution of Healthcare "City Polyclinic No. 4", Saint Petersburg, Russian Federation Regional State Budgetary Institution of Healthcare "Medical-Sanitary Unit No. 2", Tomsk, Russian Federation |
| 2139 | Recruiting | A Study to Assess the Safety and Immunogenicity of a COVID-19 Vaccine Booster in Healthy Adults | COVID-19 | Biological: Prime-2-CoV_Beta | Phase 1 | University Hospital Tuebingen, FGK Clinical Research GmbH, VisMederi srl, Staburo GmbH, Viedoc Technologies AB | OTHER | 60 | All | 18 Years ~ 55 Years | University Hospital Tubingen, Institute of Tropical Medicine, Tubingen, Baden-Wurttemberg, Germany Bernhard-Nocht-Institut fur Tropenmedizin, Hamburg, Germany |
| 2138 | Unknown status | A Study to Assess the Safety and Immunogenicity of the Coronavac Vaccine Against COVID-19 | COVID-19 | Biological: Adsorbed COVID-19 (inactivated) Vaccine | Phase 4 | D'Or Institute for Research and Education, Butantan Institute | OTHER | 1200 | All | 18 Years | Hospital Gloria D'Or - Hospitais Integrados da Gavea S/A, Rio De Janeiro, Brazil D'Or Institute for Research and Education, Rio De Janeiro, Brazil |
| 2137 | Completed | A Study to Assess the Safety, Tolerability and Preliminary Efficacy of HH-120 for the Treatment of COVID-19 | COVID-19 | Drug: HH-120 Drug: placebo |
Phase 1 | Huahui Health | INDUSTRY | 37 | All | 18 Years | Beijing Ditan Hospital,Capital Medical University, Beijing, Beijing, China Guangzhou Eighth People's,Guangzhou Medical University, Guangzhou, Guangdong, China The First Hospital of Jilin University, Changchun, Jilin, China Huashan Hospital affiliated to Fudan University, Shanghai, Shanghai, China |
| 2136 | Not yet recruiting | A Study to Compare QLS1128 With Placebo in Symptomatic Participants With Mild to Moderate COVID-19 | COVID-19 | Drug: QLS1128 Drug: Placebo |
Phase 3 | Qilu Pharmaceutical Co., Ltd. | INDUSTRY | 1220 | All | 18 Years ~ 80 Years | Qilu Pharmaceutical Co., Ltd., Jinan, Shandong, China |
